Article Figures & Data
Tables
Administered activity Largest radiation dose Effective dose Effective dose Radiopharmaceutical MBq mCi Organ mGy/MBq rad/mCi mGy rad mSv/MBq rem/mCi mSv rem 99mTc-pertechnetate*(no blocking agent) 75–150 intravenously 2–4 Upper large intestine 0.057 0.21 4.3–8.6 0.43–0.86 0.013 0.048 0.98–2.0 0.098–0.2 99mTc-sestamibi (rest)* 185–925 intravenously 5–25 Gallbladder 0.039 0.14 7.2–36 0.72–3.6 0.009 0.033 1.6–8.3 0.16–0.83 99mTc-tetrofosmin (rest)† 185–925 intravenously 5–25 Gallbladder 0.027 0.10 5.0–25 0.5–2.5 0.0069 0.026 1.3–6.4 0.13–0.64 123I-iodide (assuming 35% uptake)‡ 7.5–20 by mouth 0.2–0.6 Thyroid 4.5 17 34–90 3.4–9.0 0.22 0.81 1.6–4.4 0.16–0.44 Fetal dose Stage of gestation mGy/MBq rad/mCi Early 0.015 0.055 3 mo 0.012 0.044 6 mo 0.0084 0.031 9 mo 0.0054 0.020 Dose estimates to fetus were provided by Russell et al. (30) No information about possible placental crossover of this compound was available for use in estimating fetal doses.
Fetal dose Stage of gestation mGy/MBq rad/mCi Early 0.0096 0.036 3 mo 0.0070 0.026 6 mo 0.0054 0.020 9 mo 0.0036 0.013 Dose estimates to fetus were provided by Russell et al. (30). No information about possible placental crossover of this compound was available for use in estimating fetal doses. Separate estimates were not given for rest and exercise subjects.
Fetal dose Stage of gestation mGy/MBq rad/mCi Early 0.011 0.041 3 mo 0.022 0.081 6 mo 0.014 0.052 9 mo 0.0093 0.034 Dose estimates to fetus were provided by Russell et al. (30). Information about possible placental crossover of this compound was available and was used in estimating fetal doses.
Fetal dose Stage of gestation mGy/MBq rad/mCi Early 0.020 0.074 3 mo 0.014 0.052 6 mo 0.011 0.041 9 mo 0.0098 0.036 Dose estimates to fetus were provided by Russell et al. (30). Information about possible placental crossover of this compound was available and was used in estimating fetal doses.
Jump to section
- Article
- PREAMBLE
- I. INTRODUCTION
- II. GOALS
- III. DEFINITIONS
- IV. COMMON CLINICAL INDICATIONS
- V. QUALIFICATIONS AND RESPONSIBILITY OF PERSONNEL
- VI. PROCEDURE/SPECIFICATIONS OF THE EXAMINATION
- VII. DOCUMENTATION/REPORTING
- VIII. EQUIPMENT SPECIFICATION
- IX. QUALITY CONTROL AND IMPROVEMENT, SAFETY, INFECTION CONTROL, AND PATIENT EDUCATION CONCERNS
- X. RADIATION SAFETY IN IMAGING
- Acknowledgments
- XII. APPENDIX
- XIV. APPROVAL
- Footnotes
- XIII. REFERENCES
- Figures & Data
- Info & Metrics
Related Articles
Cited By...
- Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm
- 18F-Fluorocholine PET/CT in Primary Hyperparathyroidism: Superior Diagnostic Performance to Conventional Scintigraphic Imaging for Localization of Hyperfunctioning Parathyroid Glands
- Dual-Time-Point 18F-Fluorocholine PET/CT in Parathyroid Imaging
- Imaging of the Thyroid and Parathyroid Using a Cardiac Cadmium-Zinc-Telluride Camera: Phantom Studies
- Ectopic Parathyroid Adenoma in the Carotid Sheath
- Parathyroid Imaging with Simultaneous Acquisition of 99mTc-Sestamibi and 123I: The Relative Merits of Pinhole Collimation and SPECT/CT
- The Role of Radionuclide Imaging in the Surgical Management of Primary Hyperparathyroidism
- Parathyroid Imaging: The Importance of Pinhole Collimation with Both Single- and Dual-Tracer Acquisition